Filing Flows › Iovance Biotherapeutics (IOVA) › Recalls, complaints & regulation

Iovance Biotherapeutics (IOVA): clinical trials

Iovance Biotherapeutics (IOVA) beyond its filings: 8 active clinical trials.

Iovance Biotherapeutics' latest quarter

Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Iovance Biotherapeutics have?

8 active studies on ClinicalTrials.gov, 1 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.